FREE PSA AND CLINICALLY SIGNIFICANT ANDFATAL PROSTATE CANCER IN THE PLCO SCREENING TRIAL

被引：0
|
作者：
Yim, Kendrick
Ma, Chaoran
Carlsson, Sigrid
Lilja, Hans
D'Andrea, Vincent
Mucci, Lorelei
Penney, Kathryn
Preston, Mark
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD38-09
引用
收藏
页码：E996 / E997
页数：2
相关论文
共 50 条
  • [31] Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
    Andriole, GL
    Levin, DL
    Crawford, ED
    Gelmann, ER
    Pinsky, PF
    Chia, D
    Kramer, BS
    Reding, D
    Church, TR
    Grubb, RL
    Izmirlian, G
    Ragard, LR
    Clapp, JD
    Prorok, PC
    Gohagan, JK
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06): : 433 - 438
  • [32] Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial
    Miller, Eric A.
    Pinsky, Paul F.
    Black, Amanda
    Andriole, Gerald L.
    Pierre-Victor, Dudith
    PROSTATE, 2018, 78 (11): : 830 - 838
  • [33] PSA screening does not reduce mortality from prostate CA (PLCO)
    不详
    BJU INTERNATIONAL, 2009, 104 : 6 - 6
  • [34] Prostate-specific antigen (PSA) and PSA velocity: Competitors or collaborators in the prediction of curable and clinically significant prostate cancer
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 823 - 824
  • [35] Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial
    Landy, Rebecca
    Houghton, Lauren C.
    Berg, Christine D.
    Grubb, Robert L., III
    Katki, Hormuzd A.
    Black, Amanda
    CANCER PREVENTION RESEARCH, 2020, 13 (04) : 367 - 375
  • [36] Red meat intake and prostate cancer risk in the PLCO Cancer Screening Trial.
    Cross, AJ
    Peters, U
    Andriole, GL
    Reding, D
    Hayes, RB
    Sinha, R
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (11) : 1890S - 1890S
  • [37] THE PROSTATE GENETIC SCORE (PGS) STRATIFIES BASELINE RISK OF PROSTATE CANCER AND IMPROVES PSA PERFORMANCE IN THE PLCO TRIAL
    Liss, Michael
    Xu, Jianfeng
    Chen, Haitio
    Kader, A. Karim
    JOURNAL OF UROLOGY, 2015, 193 (04): : E896 - E897
  • [38] The Prostate, Lung, Colon, and Ovarian (PLCO) cancer screening trial: status and promise
    Andriole, GL
    Reding, D
    Hayes, RB
    Prorok, PC
    Gohagan, JK
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) : 358 - 361
  • [39] Characteristics of men with abnormal prostate-specific antigen (PSA) who had a biopsy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)
    Hocking, W. G.
    McCarty, C.
    Riley, T.
    Hickey, T.
    Burmester, J. K.
    Reding, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Stallings, FL
    Ford, ME
    Simpson, NK
    Fouad, M
    Jernigan, JC
    Trauth, JM
    Miller, DS
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 379S - 389S
12345